Datasheet

Bst2 Antibody
CATALOG NUMBER: 4661

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Rat: (83%)
TESTED APPLICATIONS:ELISA, WB
APPLICATIONS:Bst2 antibody can be used for detection of Bst2 by Western blot at 1 - 2 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1224 - Daudi Cell Lysate
IMMUNOGEN:Bst2 antibody was raised against a 18 amino acid synthetic peptide near the amino terminus of the mouse Bst2.

The immunogen is located within amino acids 60 - 110 of Bst2.
HOST SPECIES:Rabbit

Properties

PURIFICATION:Bst2 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:Bst2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:Bst2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:Bst2 Antibody: GREG, Bst-2, CD317, C87040, DAMP-1, 2310015I10Rik, Bone marrow stromal antigen 2, BST-2
ACCESSION NO.:AAH87949
PROTEIN GI NO.:56971124
OFFICIAL SYMBOL:Bst2
GENE ID:69550

Background

BACKGROUND:Bst2 Antibody: Bst2 was first identified as a novel terminal B-cell-restricted antigen termed HM1.24 that is expressed on certain bone marrow cells as well as other tissues. The surface expression of Bst2 on fibroblast cell lines facilitated the stromal cell-dependent growth of DW34, a pre-B-cell line, suggesting that this protein is involved in pre-B-cell growth. Later experiments also showed it to be upregulated in several myeloma cells. More recently, Bst2 was identified an inhibitor of retroviral release from human cells whose activity is antagonized by the HIV-1 accessory protein Vpu. While Bst2 caused retention of virions on cell surfaces or endocytosis into Bst2-positive compartments, its depletion abolished the viral requirement for Vpu for virus release. This activity may represent a potential therapeutic strategy for the treatment of HIV/AIDS.
REFERENCES: 1) Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood1994; 84:1922-30.
2) Ishikawa J, Kaisho T, Tomizawa H, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics1995; 26:527-34.
3) Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun.1999; 258:583-91.
4) Neil SJ, Zang T, and Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature2008; 451:425-30.

For Research Use Only